Morning Brew Daily hosts argue Eli Lilly’s (LLY) “Mounjaro economy” is replacing the “Ozempic economy,” as Eli Lilly controls 60% of the GLP-1 market. Lilly’s Q1 2026 revenue hit $19.80 billion, up 55 ...

A federal judge on Wednesday dismissed part of Eli Lilly's lawsuit against the Houston-based Empower Pharmacy — the latest development in the pharmaceutical giant's bid to curb sales of cheaper, ...

Eli Lilly remains well-positioned in the obesity treatment market despite early script underperformance of Foundayo versus Novo Nordisk's oral Wegovy. LLY's long-term advantage lies in small molecule ...

Eli Lilly (LLY +2.24%) became the first healthcare company to reach $1 trillion in market cap last year. However, given its poor start to 2026, it has fallen well below that. Entering trading on ...

A GLP-1 weight loss pill, already on sale in the United States, has hit a regulatory snag. The Food and Drug Administration has asked U.S. drugmaker Eli Lilly to collect more long-term safety data on ...

April 9 (UPI) --Eli Lilly announced that its GLP-1 weight-loss pill is available for purchase in the United States starting Thursday, little more than a week after the Food and Drug Administration ...

Eli Lilly has rolled out Foundayo, its oral GLP-1 pill, directly to consumers through its LillyDirect cash-pay channel, as well as to telehealth providers and pharmacies across the U.S. The drug is a ...

Eli Lilly (LLY) generated $65.18B in full-year 2025 revenue, up 44.7% year-over-year, driven by its GLP-1 franchises Mounjaro and Zepbound which command 60% of the weight-loss market, with 2026 ...

Eli Lilly has published a video about how medicines affect lives to mark its 150th anniversary and the arrival of college basketball stars in its home city. Indianapolis-based Lilly will celebrate 150 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The FDA approval of the GLP-1 ...

Foundayo, a once-daily oral GLP-1 medication approved for obesity and weight-related issues, ranges in cost from $25 to $349 per month Scott Olson/Getty Drugmaker Eli Lilly has been approved to sell a ...

The U.S. Food and Drug Administration’s approval of Eli Lilly’s once-daily pill orforglipron as a weight loss and obesity treatment this week was the fastest approval of a new medication in decades.